Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program, but your physician must apply for you. https://bit.ly/4uWZ9C5 #OncSky
Daraxonrasib, the first KRAS drug for pancreatic cancer, is now available through an expanded access program.